GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kezar Life Sciences Inc (FRA:2KZ) » Definitions » YoY EBITDA Growth

Kezar Life Sciences (FRA:2KZ) YoY EBITDA Growth : 5.02% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Kezar Life Sciences YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Kezar Life Sciences's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 5.02%.

Kezar Life Sciences's EBITDA per Share for the three months ended in Mar. 2024 was €-0.27.


Kezar Life Sciences YoY EBITDA Growth Historical Data

The historical data trend for Kezar Life Sciences's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kezar Life Sciences YoY EBITDA Growth Chart

Kezar Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial 22.59 52.86 -18.24 -4.17 -35.57

Kezar Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.30 -32.46 -20.92 -70.82 5.02

Kezar Life Sciences YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Kezar Life Sciences's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-1.254--0.925)/ | -0.925 |
=-35.57 %

Kezar Life Sciences's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Mar. 2023 )) / | EBITDA per Share (Q: Mar. 2023 )) |
=(-0.265--0.279)/ | -0.279 |
=5.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kezar Life Sciences YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Kezar Life Sciences's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Kezar Life Sciences (FRA:2KZ) Business Description

Traded in Other Exchanges
Address
4000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program.

Kezar Life Sciences (FRA:2KZ) Headlines

No Headlines